Progyny [PGNY] vs CVS Health [CVS] Detailed Stock Comparison

Progyny

NASDAQ
Loading...

CVS Health

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Progyny wins in 8 metrics, CVS Health wins in 11 metrics, with 0 ties. CVS Health appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricProgynyCVS HealthBetter
P/E Ratio (TTM)34.9021.58CVS Health
Price-to-Book Ratio3.411.27CVS Health
Debt-to-Equity Ratio5.56106.67Progyny
PEG Ratio3.14-0.51CVS Health
EV/EBITDA18.4911.95CVS Health
Profit Margin (TTM)4.28%1.18%Progyny
Operating Margin (TTM)7.32%2.80%Progyny
EBITDA Margin (TTM)7.32%2.80%Progyny
Return on Equity10.94%5.88%Progyny
Return on Assets (TTM)6.57%2.29%Progyny
Free Cash Flow (TTM)$173.70M$6.33BCVS Health
Dividend YieldN/A3.01%N/A
1-Year Return26.32%19.97%Progyny
Price-to-Sales Ratio (TTM)1.430.26CVS Health
Enterprise Value$1.49B$167.01BCVS Health
EV/Revenue Ratio1.200.44CVS Health
Gross Profit Margin (TTM)23.72%13.74%Progyny
Revenue per Share (TTM)$14$305CVS Health
Earnings per Share (Diluted)$0.59$3.59CVS Health
Beta (Stock Volatility)1.340.61CVS Health
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Progyny vs CVS Health Stock Performance Analysis

Loading Price Chart...

Progyny
CVS Health
Progyny Stock Overview | CVS Health Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Progyny-1.94%-4.05%-12.53%-4.05%-11.06%16.13%
CVS Health-0.84%2.27%5.69%14.92%14.78%75.24%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Progyny26.32%-45.11%-28.73%29.17%29.17%29.17%
CVS Health19.97%-12.19%30.45%-24.03%147.97%202.93%

News Based Sentiment: Progyny vs CVS Health

Progyny

News based Sentiment: MIXED

Progyny's Q2 2025 earnings presented a mixed picture, with revenue exceeding expectations but EPS falling short. This creates a somewhat uncertain outlook, making it a moderately important development for investors to consider.

View Progyny News Sentiment Analysis

CVS Health

News based Sentiment: MIXED

September presented a mixed bag for CVS Health, with strong earnings and strategic investments offset by significant legal challenges like the Omnicare bankruptcy and ongoing lawsuits. While the market reacted positively to some news, the legal liabilities and potential financial impacts create uncertainty, making it a moderately important month for investors.

View CVS Health News Sentiment Analysis

Performance & Financial Health Analysis: Progyny vs CVS Health

MetricPGNYCVS
Market Information
Market Cap i$1.79B$98.78B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,040,7926,881,243
90 Day Avg. Volume i1,058,1147,195,044
Last Close$20.19$76.84
52 Week Range$13.39 - $26.76$43.56 - $79.20
% from 52W High-24.55%-2.98%
All-Time High$68.32 (Nov 01, 2021)$113.65 (Jul 27, 2015)
% from All-Time High-70.45%-32.39%
Growth Metrics
Quarterly Revenue Growth0.10%0.08%
Quarterly Earnings Growth0.04%-0.42%
Financial Health
Profit Margin (TTM) i0.04%0.01%
Operating Margin (TTM) i0.07%0.03%
Return on Equity (TTM) i0.11%0.06%
Debt to Equity (MRQ) i5.56106.67
Cash & Liquidity
Book Value per Share (MRQ)$6.04$61.07
Cash per Share (MRQ)$3.55$11.18
Operating Cash Flow (TTM) i$202.00M$7.57B
Levered Free Cash Flow (TTM) i$194.61M$5.83B
Dividends
Last 12-Month Dividend Yield iN/A3.01%
Last 12-Month Dividend iN/A$2.01

Valuation & Enterprise Metrics Analysis: Progyny vs CVS Health

MetricPGNYCVS
Price Ratios
P/E Ratio (TTM) i34.9021.58
Forward P/E i27.0911.96
PEG Ratio i3.14-0.51
Price to Sales (TTM) i1.430.26
Price to Book (MRQ) i3.411.27
Market Capitalization
Market Capitalization i$1.79B$98.78B
Enterprise Value i$1.49B$167.01B
Enterprise Value Metrics
Enterprise to Revenue i1.200.44
Enterprise to EBITDA i18.4911.95
Risk & Other Metrics
Beta i1.340.61
Book Value per Share (MRQ) i$6.04$61.07

Financial Statements Comparison: Progyny vs CVS Health

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PGNYCVS
Revenue/Sales i$332.87M$94.59B
Cost of Goods Sold i$253.90M$80.19B
Gross Profit i$78.97M$14.40B
Research & Development iN/AN/A
Operating Income (EBIT) i$24.36M$3.37B
EBITDA i$25.56M$4.56B
Pre-Tax Income i$27.08M$2.62B
Income Tax i$9.97M$835.00M
Net Income (Profit) i$17.11M$1.78B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PGNYCVS
Cash & Equivalents i$109.24M$10.08B
Total Current Assets i$567.69M$73.19B
Total Current Liabilities i$237.13M$88.96B
Long-Term Debt i$26.00M$73.63B
Total Shareholders Equity i$467.16M$77.11B
Retained Earnings i$159.37M$63.77B
Property, Plant & Equipment i$42.69M$28.56B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PGNYCVS
Operating Cash Flow i$27.84M$3.96B
Capital Expenditures i$-2.84M$-743.00M
Free Cash Flow i$46.97M$3.81B
Debt Repayment iN/A$-743.00M
Common Stock Repurchase i$0$0

Short Interest & Institutional Ownership Analysis

MetricPGNYCVS
Shares Short i6.87M23.62M
Short Ratio i7.443.26
Short % of Float i0.11%0.02%
Average Daily Volume (10 Day) i1,040,7926,881,243
Average Daily Volume (90 Day) i1,058,1147,195,044
Shares Outstanding i85.31M1.26B
Float Shares i79.59M1.27B
% Held by Insiders i0.08%0.01%
% Held by Institutions i1.04%0.88%

Dividend Analysis & Yield Comparison: Progyny vs CVS Health

MetricPGNYCVS
Last 12-Month Dividend iN/A$2.01
Last 12-Month Dividend Yield iN/A3.01%
3-Year Avg Annual Dividend iN/A$2.28
3-Year Avg Dividend Yield iN/A0.87%
3-Year Total Dividends iN/A$6.85
Ex-Dividend DateN/AApr 22, 2025